ARTICLE | Product Development
Bourla’s breadcrumbs to value
How Bourla could reshape drug pricing at Pfizer
October 13, 2018 1:55 AM UTC
Incoming CEO Albert Bourla has spent only a few of his 25 years at Pfizer Inc. in the pharma’s innovative drugs business, but there are signs he already has laid the groundwork for innovating how the company’s drugs are priced.
On Oct. 1, Pfizer announced that Bourla will take the reins Jan. 1, 2019, succeeding Ian Read, who will remain as chairman. ...